US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US8007784B1
(en)
|
1996-06-27 |
2011-08-30 |
Albany Medical College |
Antigenic modulation of cells
|
US6548263B1
(en)
|
1997-05-29 |
2003-04-15 |
Cellomics, Inc. |
Miniaturized cell array methods and apparatus for cell-based screening
|
AU7987898A
(en)
*
|
1997-06-26 |
1999-01-19 |
Albany Medical College |
Antigenic modulation of viral particules
|
AU9402198A
(en)
*
|
1997-09-26 |
1999-04-23 |
Becton Dickinson & Company |
Preparing conjugates using polyethylene glycol linkers
|
US6747003B1
(en)
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
WO1999043357A1
(en)
*
|
1998-02-25 |
1999-09-02 |
Micrologix Biotech Inc. |
Indolicidin and cationic peptides conjugated with polymers
|
CN100335503C
(zh)
|
1998-04-28 |
2007-09-05 |
应用研究系统Ars股份公司 |
多元醇干扰素β偶联物
|
WO1999065506A2
(en)
*
|
1998-06-12 |
1999-12-23 |
Micrologix Biotech Inc. |
Cancer therapy with indolicidin or cationic peptides and their polymer conjugates
|
ES2257884T3
(es)
|
1998-10-16 |
2006-08-01 |
Biogen Idec Ma Inc. |
Conjugados de polimero e interferon beta-1a y sus usos.
|
EA005005B1
(ru)
|
1998-10-16 |
2004-10-28 |
Байоджен, Инк. |
ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
|
EP1144452B1
(de)
*
|
1998-11-03 |
2006-01-11 |
Centocor, Inc. |
Modifizierte antikörper und antikörper-fragmente mit verlängerter aktivitätsdauer
|
WO2000032772A2
(en)
*
|
1998-11-30 |
2000-06-08 |
Eli Lilly And Company |
Erythropoietic compounds
|
US6958212B1
(en)
|
1999-02-01 |
2005-10-25 |
Eidgenossische Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
WO2000044808A1
(en)
|
1999-02-01 |
2000-08-03 |
Hubbell Jeffrey A |
Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US6309633B1
(en)
*
|
1999-06-19 |
2001-10-30 |
Nobex Corporation |
Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
|
MXPA02006795A
(es)
|
2000-01-10 |
2005-04-19 |
Maxygen Holdings Ltd |
Conjugados g-csf.
|
US6806063B2
(en)
|
2000-02-11 |
2004-10-19 |
Maxygen Aps |
Factor VII or VIIa-like molecules
|
WO2001079442A2
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7291673B2
(en)
|
2000-06-02 |
2007-11-06 |
Eidgenossiche Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
EP1292709B1
(de)
*
|
2000-06-02 |
2012-01-18 |
Eidgenössische Technische Hochschule Zürich |
Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
US6423826B1
(en)
*
|
2000-06-30 |
2002-07-23 |
Regents Of The University Of Minnesota |
High molecular weight derivatives of vitamin K-dependent polypeptides
|
US7160540B2
(en)
|
2000-06-30 |
2007-01-09 |
Regents Of The University Of Minnesota |
Methods for detecting activity of clottings factors
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
EP2184291A1
(de)
|
2000-08-18 |
2010-05-12 |
Dyax Corp. |
Bindepolypeptide für B-Lymphozyten-Stimulatorprotein (BLyS)
|
US20040082765A1
(en)
*
|
2000-10-16 |
2004-04-29 |
Teruo Nakamura |
Peg-modified erythropoietin
|
CA2426692C
(en)
|
2000-10-19 |
2011-01-25 |
Eidgenossische Technische Hochschule Zurich |
Block copolymers for multifunctional self-assembled systems
|
ATE505204T1
(de)
|
2000-12-20 |
2011-04-15 |
Hoffmann La Roche |
Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
|
ES2361824T3
(es)
|
2000-12-20 |
2011-06-22 |
F. Hoffmann-La Roche Ag |
Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
|
DE10102878A1
(de)
*
|
2001-01-23 |
2002-08-01 |
Haemosys Gmbh |
Oligo- oder Polyalkylengekoppelte Thrombininhibitoren
|
SK11882003A3
(sk)
|
2001-02-27 |
2004-03-02 |
Maxygen Aps |
Variant štandardného ľudského interferónu ß, nukleotidová sekvencia kódujúca tento variant, expresný vektor a hostiteľská bunka s jej obsahom, farmaceutický prostriedok s obsahom uvedeného variantu a jeho použitie
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
AU2002249096B2
(en)
*
|
2001-03-22 |
2007-06-28 |
Novo Nordisk Health Care Ag |
Coagulation factor VII derivatives
|
US6838076B2
(en)
|
2001-05-21 |
2005-01-04 |
Nektar Therapeutics |
Pulmonary administration of chemically modified insulin
|
PT1572874E
(pt)
|
2001-05-25 |
2013-12-11 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente aos receptores de trail
|
ES2320979T3
(es)
|
2001-09-24 |
2009-06-01 |
Imperial Innovations Limited |
Pyy-36 para la reduccion o prevencion de la obesidad.
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
JP5424521B2
(ja)
|
2001-12-21 |
2014-02-26 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
EP1474163A2
(de)
|
2002-01-10 |
2004-11-10 |
Imperial College Innovations Limited |
Veränderung des fütterungsverhaltens
|
PL397261A1
(pl)
|
2002-01-18 |
2012-03-26 |
Biogen Idec Ma Inc. |
Aktywowany polimer glikolu polialkilenowego, kompozycja i kompozycja farmaceutyczna oraz ich zastosowanie
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
JP2005528372A
(ja)
*
|
2002-03-26 |
2005-09-22 |
バイオシネクサス インコーポレイテッド |
抗菌ポリマー複合体
|
PT1499719E
(pt)
|
2002-04-30 |
2011-02-09 |
Bayer Healthcare Llc |
Variantes polipeptídicas do factor vii ou viia
|
JP4634145B2
(ja)
*
|
2002-06-21 |
2011-02-16 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
ペジル化されたvii因子糖形体
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
EP1681303B1
(de)
*
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylierte Polypeptide, besonders HASyliertes Erythropoietin
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
EP2085470B1
(de)
|
2003-03-20 |
2012-05-16 |
Bayer HealthCare LLC |
FVII oder FVIIa Varianten
|
EP1615945B1
(de)
|
2003-04-09 |
2011-09-28 |
BioGeneriX AG |
Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
|
ATE395101T1
(de)
*
|
2003-04-15 |
2008-05-15 |
Opperbas Holding Bv |
Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
|
NZ573412A
(en)
|
2003-06-19 |
2010-09-30 |
Maxygen Holdings Ltd |
Factor VII or VIIa Gla domain variants
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
CA2542179A1
(en)
|
2003-10-10 |
2005-04-21 |
Novo Nordisk A/S |
Il-21 derivatives
|
EP2633866A3
(de)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Kombinationstherapie
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
SI1696947T1
(sl)
|
2003-12-19 |
2014-05-30 |
F. Hoffmann-La Roche Ag |
Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih
|
ES2392061T3
(es)
|
2003-12-22 |
2012-12-04 |
Regentis Biomaterials Ltd. |
Matriz que comprende un esqueleto proteico de origen natural reticulado
|
US7842667B2
(en)
|
2003-12-22 |
2010-11-30 |
Regentis Biomaterials Ltd. |
Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
|
EP1718664A4
(de)
|
2004-02-02 |
2008-08-13 |
Ambrx Inc |
Modifizierte menschliche vierhelix-bündel-peptide und ihre verwendungen
|
AU2005211725B2
(en)
|
2004-02-09 |
2010-07-15 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR101699142B1
(ko)
|
2004-06-18 |
2017-01-23 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
EP1771066A2
(de)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1
|
JP2008506704A
(ja)
*
|
2004-07-16 |
2008-03-06 |
ネクター セラピューティクス アラバマ,コーポレイション |
Gm−csf成分およびポリマーの複合体
|
WO2006015512A1
(fr)
*
|
2004-08-11 |
2006-02-16 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
Arginine déiminase modifiée
|
EP1814573B1
(de)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
|
US7597907B2
(en)
*
|
2004-11-05 |
2009-10-06 |
Trustees Of The University Of Pennsylvania |
Antioxidant polymer nanocarriers for use in preventing oxidative injury
|
US8080391B2
(en)
|
2004-12-22 |
2011-12-20 |
Ambrx, Inc. |
Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
|
ATE541934T1
(de)
|
2004-12-22 |
2012-02-15 |
Ambrx Inc |
Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
|
BRPI0519170A8
(pt)
|
2004-12-22 |
2018-05-08 |
Ambrx Inc |
formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
|
US7939496B2
(en)
|
2004-12-22 |
2011-05-10 |
Ambrx, Inc. |
Modified human growth horomone polypeptides and their uses
|
MX2007008229A
(es)
|
2005-01-10 |
2007-09-11 |
Neose Technologies Inc |
Factor estimulador de colonias de granulocitos glicopegilado.
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
US9505867B2
(en)
|
2005-05-31 |
2016-11-29 |
Ecole Polytechmique Fédérale De Lausanne |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
CN101247821B
(zh)
|
2005-06-03 |
2013-01-23 |
Ambrx公司 |
经改良人类干扰素分子和其用途
|
US8633300B2
(en)
|
2005-06-17 |
2014-01-21 |
Novo Nordisk Healthcare Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
EP1933873A4
(de)
|
2005-10-13 |
2009-12-02 |
Human Genome Sciences Inc |
Verfahren und zusammensetzung zur verwendung bei der behandlung von patienten mit autoantikörper-positiven leiden
|
US20070099820A1
(en)
|
2005-10-19 |
2007-05-03 |
Smartcells, Inc. |
Polymer-drug conjugates
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
CN106443006A
(zh)
|
2005-11-16 |
2017-02-22 |
Ambrx公司 |
包括非天然氨基酸的方法和组合物
|
CA2640661A1
(en)
|
2006-02-01 |
2007-08-09 |
Arana Therapeutics Limited |
Domain antibody construct
|
WO2007124461A2
(en)
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compounds
|
MX2008014685A
(es)
|
2006-05-24 |
2008-11-27 |
Novo Nordisk Healthcare Ag |
Analogos de factor ix con semivida prolongada in vivo.
|
CN101516388B
(zh)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
US9505823B2
(en)
|
2006-08-07 |
2016-11-29 |
TEV A Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
MX2009002523A
(es)
|
2006-09-08 |
2009-03-20 |
Ambrx Inc |
Polipeptido de plasma humano modificado o andamios fc y sus usos.
|
DK2064333T3
(da)
|
2006-09-08 |
2014-05-05 |
Ambrx Inc |
Suppressor-trna-transkription i hvirveldyrceller
|
CN106190983B
(zh)
|
2006-09-08 |
2019-05-28 |
Ambrx公司 |
用于脊椎动物细胞的杂合抑制tRNA
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20100075375A1
(en)
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
JP5876208B2
(ja)
|
2006-12-15 |
2016-03-02 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
延長されたinvivo半減期を有する第VIIa因子−(ポリ)シアル酸結合体
|
KR20140012199A
(ko)
|
2007-03-30 |
2014-01-29 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
EP2145884B1
(de)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledionderivat
|
PL2144923T3
(pl)
|
2007-04-03 |
2013-12-31 |
Biogenerix Ag |
Sposoby leczenia z użyciem glikopegilowanego G-CSF
|
JP2010525821A
(ja)
|
2007-05-02 |
2010-07-29 |
アンブルックス,インコーポレイテッド |
修飾IFNβポリペプチドおよびこれらの使用
|
EP2170919B8
(de)
|
2007-06-12 |
2016-01-20 |
ratiopharm GmbH |
Verbessertes verfahren zur herstellung von nukleotidzuckern
|
US7927629B2
(en)
|
2007-10-27 |
2011-04-19 |
The Trustees Of The University Of Pennsylvania |
Method and compositions for polymer nanocarriers containing therapeutic molecules
|
US8568786B2
(en)
|
2007-10-27 |
2013-10-29 |
The Trustees Of The Universtiy Of Pennsylvania |
Method and compositions for polymer nanocarriers containing therapeutic molecules
|
KR101656107B1
(ko)
|
2007-11-20 |
2016-09-08 |
암브룩스, 인코포레이티드 |
변형된 인슐린 폴리펩티드 및 이의 용도
|
NZ602170A
(en)
|
2008-02-08 |
2014-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
DK2257311T3
(da)
|
2008-02-27 |
2014-06-30 |
Novo Nordisk As |
Konjugerede Faktor VIII-Molekyler
|
WO2009118300A1
(en)
|
2008-03-25 |
2009-10-01 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
CA2729851C
(en)
|
2008-07-23 |
2019-01-15 |
Ambrx, Inc. |
Modified bovine g-csf polypeptides and their uses
|
CN107022020A
(zh)
|
2008-09-26 |
2017-08-08 |
Ambrx公司 |
修饰的动物促红细胞生成素多肽和其用途
|
US9121024B2
(en)
|
2008-09-26 |
2015-09-01 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
EP2356228B1
(de)
|
2008-11-25 |
2023-05-03 |
École Polytechnique Fédérale de Lausanne (EPFL) |
Blockcopolymere und verwendungen davon
|
WO2010088286A1
(en)
|
2009-01-28 |
2010-08-05 |
Smartcells, Inc. |
Synthetic conjugates and uses thereof
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
CA2754950A1
(en)
|
2009-03-20 |
2010-09-23 |
Smartcells, Inc. |
Terminally-functionalized conjugates and uses thereof
|
US8580732B2
(en)
|
2009-04-07 |
2013-11-12 |
Duke University |
Peptide therapy for hyperglycemia
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
EP3925670A1
(de)
|
2009-12-17 |
2021-12-22 |
Children's Medical Center, Corp. |
Aus saposin-a gewonnene peptide und verwendungen davon
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
CN107674121A
(zh)
|
2009-12-21 |
2018-02-09 |
Ambrx 公司 |
经过修饰的牛促生长素多肽和其用途
|
EP2542569B1
(de)
|
2010-03-05 |
2020-09-16 |
Omeros Corporation |
Chimäre hemmermoleküle mit komplementaktivierung
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
GB201007356D0
(en)
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIIa
|
US20120135912A1
(en)
|
2010-05-10 |
2012-05-31 |
Perseid Therapeutics Llc |
Polypeptide inhibitors of vla4
|
EP2580239A1
(de)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krebs mittels modulation von mammalian-ste20-like-kinase 3
|
EP3572091B1
(de)
|
2010-08-17 |
2023-12-13 |
Ambrx, Inc. |
Modifizierte relaxinpolypeptide und deren verwendungen
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
EP2614080A1
(de)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphoryliertes twist1 und metastasen
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
EP2640738A1
(de)
|
2010-11-15 |
2013-09-25 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Antimykotische wirkstoffe
|
EP2474612A1
(de)
|
2011-01-05 |
2012-07-11 |
University College Dublin, National University of Ireland Dublin |
Affinitätstrennungsmittel und ihre Verwendungen zur Trennung, Reinigung und Konzentration von Zielmolekülen
|
US9181553B2
(en)
|
2011-06-06 |
2015-11-10 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Method of treatment of breast cancers over-expressing the SHP2 signature genes
|
US9382305B2
(en)
|
2011-07-01 |
2016-07-05 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
WO2013068432A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
CA2860226C
(en)
|
2011-12-22 |
2022-10-18 |
Randolph S. Watnick |
Saposin-a derived peptides and uses thereof
|
US20140363448A1
(en)
|
2012-01-02 |
2014-12-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
US9474810B2
(en)
*
|
2012-03-02 |
2016-10-25 |
General Electric Company |
Superparamagnetic nanoparticles with PEG substituted α-hydroxy phosphonate shells
|
US8993614B2
(en)
|
2012-03-15 |
2015-03-31 |
F. Hoffmann-La Roche Ag |
Substituted pyrrolidine-2-carboxamides
|
WO2013144240A1
(en)
|
2012-03-29 |
2013-10-03 |
Friedrich Miescher Institute For Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
US20150086524A1
(en)
|
2012-04-16 |
2015-03-26 |
Cantab Biopharmaceuticals Patents Limited |
Optimised subcutaneous therapeutic agents
|
BR112014030278A2
(pt)
|
2012-06-08 |
2017-06-27 |
Sutro Biopharma Inc |
anticorpo, e, composição.
|
EP3135690A1
(de)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
|
EP2866831A1
(de)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
|
WO2014006114A1
(en)
|
2012-07-05 |
2014-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
KR102182800B1
(ko)
|
2012-08-31 |
2020-11-25 |
서트로 바이오파마, 인크. |
아지도 기를 포함하는 변형된 아미노산
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US10711106B2
(en)
|
2013-07-25 |
2020-07-14 |
The University Of Chicago |
High aspect ratio nanofibril materials
|
WO2015019286A1
(en)
|
2013-08-07 |
2015-02-12 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment friedreich's ataxia
|
EP3055298B1
(de)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
|
CN104007079B
(zh)
*
|
2014-04-18 |
2016-06-29 |
深圳赛保尔生物药业有限公司 |
重组人促红素聚乙二醇化反应液的光谱检测法及应用
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
EP3157535A1
(de)
|
2014-06-23 |
2017-04-26 |
Friedrich Miescher Institute for Biomedical Research |
Verfahren zur auslösung der novo-bildung von heterochromatin und/oder zur epigenetischen abschaltung mit kleinen rnas
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
TWI705071B
(zh)
|
2014-10-24 |
2020-09-21 |
美商必治妥美雅史谷比公司 |
經修飾之fgf-21多肽及其用途
|
CN107921103A
(zh)
|
2015-08-12 |
2018-04-17 |
细胞机械股份有限公司 |
涉及长半衰期凝血复合物的方法和组合物
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
SG10201912034UA
(en)
|
2017-02-08 |
2020-02-27 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
US20200216563A1
(en)
|
2017-08-10 |
2020-07-09 |
Friedrich Miescher Institute For Biomedical Research |
Hdac6 and protein aggregation
|
CN116948006A
(zh)
|
2018-09-11 |
2023-10-27 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其用途
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
KR20210136014A
(ko)
|
2019-02-12 |
2021-11-16 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
|
MX2022011163A
(es)
|
2020-03-11 |
2022-10-18 |
Ambrx Inc |
Conjugados de polipeptidos de interleucina-2 y sus usos.
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
AU2022249223A1
(en)
|
2021-04-03 |
2023-10-12 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
CN114230739B
(zh)
*
|
2021-12-14 |
2023-08-11 |
西安交通大学 |
一种线性-非线性嵌段聚合物及其制备方法
|